Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines that target the cellular nutrient signaling proteins regulating mTORC1 activation to treat serious diseases including neurological and fibrotic disorders, immunometabolism and certain rare diseases, today announced that George P. Vlasuk, PhD, President and Chief Executive Officer, will present a corporate overview at the UBS Global Healthcare Conference in New York on Tuesday, May 22, 2018 at 4:00 p.m. Eastern time.

About Navitor

Navitor Pharmaceuticals, Inc., is a biopharmaceutical company discovering and developing novel medicines that target the nutrient sensing pathways that regulate mTORC1, a master regulator of cellular growth and metabolism. The company’s proprietary drug discovery platform unlocks the therapeutic potential of mTOR by bringing together deep knowledge into nutrient sensors, proprietary biological tools and expertise regarding the correlation of mTORC1 activity in disease. Navitor’s small molecule therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activation to address a wide range of diseases, including neurological and fibrotic disorders, immunometabolism and certain rare diseases. The company’s founding intellectual property is based on groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Innovation – JJDC, Inc., SR One, Ltd., Brace Pharma Capital, Remeditex Ventures and Sanofi Ventures. For more information, please visit www.navitorpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005150/en/

The Yates Network
Kathryn Morris, 914-204-6412
[email protected]

Source: Navitor Pharmaceuticals, Inc.

You May Also Be Interested In

• Erasca Announces Pricing of Upsized Public Offering of Common Stock
• The Trade Desk Unlocks Activation of Convenience Store Retail Data for Digital Advertising in Japan
• Asia's Debut of LEAP East in HKCEC Marks Hong Kong's Largest Inaugural Tech Summit